Ki orKd | IC50 | Apparent slope factor | |
---|---|---|---|
nm | μm | ||
Amiodarone | 35 | 54 ± 5 | 0.72 ± 0.11 |
AY-9944 | 12 | 16 ± 6 | 0.69 ± 0.12 |
(±) -Emopamil | 19 | 7 ± 1 | 0.83 ± 0.22 |
Enclomiphene | 0.7 | 0.3 ± 0.1 | 0.68 ± 0.07 |
Ifenprodil | 6 | 14 ± 4 | 0.62 ± 0.18 |
MDL5332 | 54 | 45 ± 3 | 0.75 ± 0.12 |
MDL28815 | 0.5 | 0.014 ± 0.001 | 2.22 ± 0.32 |
Nafoxidine | 0.9 | 0.5 ± 0.1 | 0.94 ± 0.11 |
Opipramol | 3.8 | 6 ± 1 | 0.82 ± 0.10 |
Tamoxifen | 2.8 | 1.8 ± 0.1 | 0.65 ± 0.07 |
Tridemorph | 1.3 | 3 ± 0.4 | 0.88 ± 0.03 |
Trifluoperazine | 3.6 | 8 ± 2 | 0.85 ± 0.07 |
Triparanol | 14 | 7 ± 3 | 0.67 ± 0.07 |
U18666A | 1.9 | 4 ± 1 | 1.11 ± 0.02 |
Zuclomiphene | 3.0 | 2.0 ± 0.1 | 0.71 ± 0.16 |
K i or K d values were taken from Table 1, 2, and 4. SI activity was measured as described in Experimental Procedures in the absence or presence of drug.
Data shown are mean ± standard deviation (n = 3). Given in parenthesis are the SI activities in percent of control determined in the presence of 100 μm BM15766 (97 ± 5), fenpropimorph (40 ± 4), haloperidol (50 ± 8), trifluperidol (45 ± 10), 6-ketocholestanol (36 ± 10), and 7-OH-cholesterol (61 ± 5).